Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-30

Clinical Trial Update: Hepatocyte Growth Factor to Improve Functioning in PAD [Phase 2]

View source ↗

Summary

Phase 2 trial of hepatocyte growth factor to improve functioning in peripheral artery disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Hepatocyte Growth Factor (hepatocyte growth factor)

Snippet

Sponsor: Northwestern University | Conditions: Peripheral Artery Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-05-30